GlycoMimetics Offers Data on GMI-1271 Treatment of Acetaminphen-Triggered Liver Toxicity at Conference

GlycoMimetics, Inc.

today announced that collaborative research on the effects of its clinical drug candidate GMI-1271 on E-selectin, and acetaminophen- induced liver damage was accepted for an oral presentation at "Digestive Disease Week," the annual meeting of the American Gastroenterological Association, American Association for the Study of Liver Diseases, American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract. The meeting will take place May 21-24 in San Diego. The oral presentation, entitled "Alleviation of acute drug-induced liver injury following acetaminophen overdose by therapeutic blockade of E- selectin in preclinical mouse model," is scheduled for 2:15 p.m. PT on Sunday, May 22. More information on the abstract and meeting is available here. "The results in this preclinical model of liver toxicity demonstrate both the biological activity of GMI-1271 and the possible broader uses of an E-selectin antagonist. While GlycoMimetics is currently focused on developing GMI-1271 for treatment of acute myeloid leukemia (AML), this drug candidate has shown activity in pre-clinical models of multiple different diseases where E-selectin plays a functional role," said John L. Magnani, Ph.D. and Chief Scientific Officer of GlycoMimetics.